Eli Lilly shares climb on stronger revenue outlook tied to obesity drugs
The raised guidance keeps incretin franchise sales at the center of Lilly's growth story heading into the rest of the year.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly stock rose after the company issued a stronger revenue outlook that it attributed to demand for its obesity medicines.
- 02Lilly's incretin revenue trajectory shapes supply, pricing and contracting decisions that reach prescribers, pharmacies and telehealth operators.
- 03The report is a guidance update rather than new clinical data; detail on volumes, pricing and payer mix was not broken out here.
From the source
Read at finance.yahoo.comEli Lilly shares climb after stronger revenue outlook driven by obesity drugs
